{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+intramuscular+injection",
    "query": {
      "intervention": "Placebo intramuscular injection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 660,
    "total_pages": 66,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+intramuscular+injection&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T14:06:15.936Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00088478",
      "title": "Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Intramuscular Olanzapine Depot",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 402,
      "start_date": "2004-06",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2007-06-12",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 34,
      "location_summary": "National City, California • Orange, California • Rosemead, California + 31 more",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Rosemead",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088478"
    },
    {
      "nct_id": "NCT04613206",
      "title": "High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunization; Infection",
        "Transplantation Infection",
        "Influenza",
        "Solid Organ Transplant"
      ],
      "interventions": [
        {
          "name": "High Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Quadrivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2021-01-11",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04613206"
    },
    {
      "nct_id": "NCT06077487",
      "title": "Ketamine-assisted Therapy for Advanced GI Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Pain, Acute",
        "Gastrointestinal Cancers",
        "Demoralization"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Ketamine Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Meaning and Purpose therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Brian Anderson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2024-05-17",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06077487"
    },
    {
      "nct_id": "NCT01853878",
      "title": "A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell"
      ],
      "interventions": [
        {
          "name": "Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2013-06-12",
      "completion_date": "2016-08-24",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 8,
      "location_summary": "Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Paterson",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853878"
    },
    {
      "nct_id": "NCT02294058",
      "title": "Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo to interferon beta-1a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1346,
      "start_date": "2014-12-03",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2020-11-25",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02294058"
    },
    {
      "nct_id": "NCT06047444",
      "title": "A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 759,
      "start_date": "2023-10-12",
      "completion_date": "2026-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06047444"
    },
    {
      "nct_id": "NCT03911076",
      "title": "Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ASC-US",
        "ASC-H",
        "LSIL"
      ],
      "interventions": [
        {
          "name": "PVX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "PapiVax Biotech, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 70 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2019-05-22",
      "completion_date": "2022-06-08",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 6,
      "location_summary": "Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more",
      "locations": [
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Fairfield",
          "state": "Ohio"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Corpus Christi",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911076"
    },
    {
      "nct_id": "NCT01097096",
      "title": "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CAD106",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "Up to 85 Years"
      },
      "enrollment_count": 177,
      "start_date": "2010-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 5,
      "location_summary": "Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01097096"
    },
    {
      "nct_id": "NCT02982915",
      "title": "Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Aging Frailty"
      ],
      "interventions": [
        {
          "name": "Longeveron Mesenchymal Stem Cells (LMSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High Dose Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Longeveron Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "65 Years to 90 Years"
      },
      "enrollment_count": 62,
      "start_date": "2016-11",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 6,
      "location_summary": "Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02982915"
    },
    {
      "nct_id": "NCT04501796",
      "title": "A Trial of NT-I7 in COVID-19 (SPESELPIS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Double-Blind NT-I7",
          "type": "DRUG"
        },
        {
          "name": "Double-Blind Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeoImmuneTech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "19 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2020-11-27",
      "completion_date": "2023-02-23",
      "has_results": false,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-09-25T14:06:15.936Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Omaha, Nebraska",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501796"
    }
  ]
}